書籍詳細

第45回日本移植学会より

P.16 掲載の参考文献

• 1) Takahashi K, Saito K, Tanabe K et al.:Multicenter cooperative study group. First report of a seven-year survey on ABO-incompatible kidney transplantation in Japan. Clin Exp Nephrol 5:119-125, 2001.

• 2) Takahashi K, Saito K, Takahara S et al.:Excellent longterm outcome of ABO-incompatible living donor kidney Transplantation in Japan. Am J Transplant 4:1089-1096, 2004.
  pubmed

• 3) Takahashi K, Saito K:The Japanese ABO-incompatible Kidney Transplantation Committee:Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplant 13:118-122, 2006.

• 4) Takahashi K:ABO-incompatible organ transplantation. Curr Opin Organ Transplant 12:409-414, 2007.

• 5) Takahashi K:Chapter 6. Accommodation in ABO-incompatible kidney transplantation-Why do kidney grafts survive? Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004, p37-52.

• 6) Takahashi K:A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant 19 (suppl 14) :76-85, 2005.

• 7) Takahashi K:A new immunosuppressive therapy in ABO-incompatible kidney transplantation besed on a new concept of accommodation. ABO-incompatible organ transplantation from Japan. (ed, Takahahi K) , Elsevier, Amsterdam, 2006, p73-87.

• 8) Ogawa H, Mohiuddin MM, Galili U et al.:Mouse-heart grafts expressing an incompatible carbohydrate antigen. II Transition from accommodation to tolerance. Transplantation 77:366-373, 2004.
  pubmed

• 9) Galili U:Xenotransplantation and ABO-incompatible transplantation:the similarities they share. Transfus Apher Sci 35:45-58, 2006.
  pubmed

• 10) West LJ:B-cell tolerance following ABO-incompatible infant heart transplantation. Transplantation 81:301-307, 2006.
  pubmed

• 11) Takahashi K:Chapter 8. Timing of the start of immunosuppressive therapy (duration of desensitization therapy) . Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004, p94-95.

• 12) Takahashi K:ABO-incompatible kidney transplantation-Establishing a scientific framework. Elsevier, Amsterdam, 2007, p1-86.

• 13) Saito K, Nakagawa Y, Takahashi K et al:Pinpoint targeted immunosuppression; Anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplant 13:111-117, 2006.

• 14) Takahashi K:Recent findings of ABO-incompatible kidney Transplantation-classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-bloog group-related antigens during critical period preceding establishment of accommodation. Clin Exp Nephrol 11:128-141, 2007.

• 15) Tyden G, Kumlien G, Genberg H et al.:ABO-incompatible kidney transplantation without splenectomy using antigenspecific immunoadsorption and rituximab. Am J Transplant 5:145-148, 2005.
  pubmed

• 16) Kobayashi T, Saito K:A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplant 13(2) :136-140, 2006.

• 17) Alexandre GPJ, Squifflet JP, Bruyere MDE et al:Splenectomy as a prerequisite for human ABO-incompatible renal transplantation. Transplant Proc 17:138-143, 1985.

• 18) Irei T, Ohdan H, Zhou W et al:The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade:novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110:4567-4575, 2007.

• 19) Tasaki M, Yoshida Y, Miyamoto M et al.:Identification and characterization of major proteins carrying ABO blood group antigens in the human kidney. Transplantation 87 (8) :1125-1133, 2009.
  pubmed

• 20) Takahashi K, Saito K, Nakagawa Y, Tasaki M, Imai N, Hara N:Mechanism of acute antibody-mediated rejection in ABO-incompatible kidney transplantation:which anti-A/anti-B antibodies are responsible, natural or de novo? Transplant 89(5) :635-637, 2010.
  pubmed

P.20 掲載の参考文献

• 1) Alexandre GP, Squifflet JP, De Bruyere M, Latinne D, Reding R, Gianello P, Carlier M, Pirson Y:Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 19:4538-4542, 1987.

• 2) Squifflet JP, De Meyer M, Malaise J, Latinne D, Pirson Y, Alexandre GP:Lessons learned from ABO-incompatible living donor kidney transplantation:20 years later. Exp Clin Transplant 2:208-213, 2004.
  pubmed

• 3) Takahashi K:Recent findings in ABO-incompatible kidney transplantation:classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation. Clin Exp Nephrol 11:128-141, 2007.
  pubmed

P.26 掲載の参考文献

• 1) Takahashi K:A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant 19 (Suppl 14) :76-85, 2005.

• 2) Takahashi K:A new immunosuppressive therapy in ABO-incompatible kidney transplantation based on a new concept of accommodation. ABO-incompatible organ transplantation from Japan. (ed. Takahashi K) , Elsevier, Amsterdam, 2006, p73-87.

• 3) Takahashi K, Saito K, Takahara S et al.:Excellent long term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089-1096, 2004.
  pubmed

• 4) Alexandre GPJ, Squifflet JP, Bruyere MDE et al.:Splenectomy as a prerequisite for human ABO-incompatible renal transplantation. Transplant Proc 17:138-143, 1985.

• 5) Sawada T, Fuchinoue S, Teraoka S:Successful A1 to O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonalantibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 74:1207-1210, 2002.

• 6) Sawada T, Fuchinoue S, Kawase T et al.:Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 18:254-260, 2004.
  pubmed

• 7) Tyden G, Kumlien G, Fehrman I:Successful ABO-incompatible kidney transplantation without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76:730-743, 2003,
  pubmed

• 8) Tyden G, Kumlien G, Genberg H et al.:ABO-incompatible kidney transplantation without splenectomy using antigen-specific immunoadsorption and rituximab. Am J Transplant 5:145-148, 2005.
  pubmed

• 9) Saito K, Nakagfawa Y, Takahashi K et al.:Pinpoint targeted immunosuppression; Anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplant 13:111-117, 2006.

• 10) Kaplan B, Gangerni A, Thielhe J et al.:Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 83:99-100, 2007.

• 11) Locke JE, Zachary AA, Haas M et al, :The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 7:842-846, 2007.
  pubmed

• 12) Ishida H, Omoto K, Shimizu T et al.:Usefulness of splenectomy for chronic active antibody-mediated rejection after renal transplant. Transplant Intemational 21:602-604, 2008.

• 13) Teraoka S, Sato S, Kai K et al.:Early steroid withdrawal protocol using Basiliximab in kidney transplantation. Transplant Proc 36:478-482, 2004.

P.33 掲載の参考文献

• 1) Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S et al.:Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73:1959-1961, 2002.
  pubmed

• 2) Haga H, Egawa H, Shirase T, Miyagawa A, Sakurai T et al.:Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. Liver Transpl 10(1) :16-27, 2004.
  pubmed

P.34 掲載の参考文献

• 3) Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H et al.:Rituximab, IVIG, and plasma exchange without graft local infusion treatment:a new protocol in ABO incompatible living donor liver transplantation. Transplantation 88:303-307, 2009.
  pubmed

• 4) Urbani L, Mazzoni A, Bianco I, Grazzini T, De Simone P et al:The role of immunomodulation in ABO-incompatible adult liver transplant recipients. J Clin Apher 23(2) :55-62, 2008.
  pubmed

• 5) Egawa H, Ohmori K, Haga H, Tsuji H, Yurugi K et al:B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 13(4) :579-588, 2007.
  pubmed

P.38 掲載の参考文献

• 1) Tanabe M, Shimazu M, Wakabayashi G et al.:Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73 (12) :1959-1961, 2002.
  pubmed

• 2) Egawa H, Teramukai S, Haga H et al:Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 47(1) :143-152, 2008.
  pubmed

• 3) Irei T, Ohdan H, Zhou W et al.:The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-l cell differentiation blockade:novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110(13) :4567-4575, 2007.

• 4) Zhou W, Ohdan H, Tanaka Y, Hara H, Tokita D et al.:NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant. Transpl Immunol 12(1) :9-18, 2003.

• 5) Arnold LW, McCray SK, Tatu C, Clarke SH:Identification of a precursor to phosphatidyl choline-specific B-1 cells suggesting that B-1 cells differentiate from splenic conventional B cells in vivo:cyclosporin A blocks differentiation to B-1. J Immunol 164(6) :2924-2930, 2000.

• 6) Zhou W, Ohdan H, Asahara T:Calcineurin inhibitors block B-1 cell differentiation:the relevance to immunosuppressive treatment in ABO-incompatible transplantation. Transplant Proc 37(4) :1808-1811, 2005.

• 7) Ohdan H, Swenson KG, Kruger Gray HS, Yang YG, Xu Y et al:Mac-1-negative B-1b phenotype of natural antibody-producing cells, including those responding to Gal alpha 1, 3Gal epitopes in alpha 1, 3-galactosyltransferase-deficient mice. J Immunol 165(10) :5518-5529, 2000.
  pubmed

• 8) Grailer A, Nichols J, Hullett D, Sollinger HW, Burlingham WJ:Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and DAB486 IL-2. Transplant Proc 23(1Pt 1) :314-315, 1991.

P.39 掲載の参考文献

• 9) Onoe T, Ohdan H, Tokita D et al:Liver Sinusoidal endothelial Cells Tolerize T Cells across MHC Barriers in Mice. J Immunol 175(1) :139-146, 2005.
  pubmed

• 10) Tokita D, Shishida M, Ohdan H et al.:Liver sinusoidal endothelial cells that endocytose allogeneic cells suppress T cells with indirect allospecificity. J Immunol 177:3615-3624, 2006.
  pubmed

• 11) Ohdan H, Zhou W, Tanaka Y, Irei T, Fuchimoto Y et al.:Evidence of immune tolerance to blood group antigens in a case of ABO-incompatible pediatric liver transplantation. Am J Transplant 7(9) :2190-2194, 2007.

P.45 掲載の参考文献

• 1) Demetris AJ, Jaffe R, Tzakis A et al.:Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 132:489-502, 1988.
  pubmed

• 2) Gugenheim J, Samuel D, Reynes M et al.:Liver transplantation across ABO blood group barriers. Lancet 336:519-523, 1990.
  pubmed

• 3) Farges O, Kalil AN, Samuel D et al.:The use of ABO-incompatible grafts in liver transplantation:a life-saving procedure in highly selected patients. Transplantation 59:1124-1133, 1995.
  pubmed

• 4) Egawa H, Oike F, Buhler L et al:Impact of recipient age on outcome of ABO-incopatible living-donor liver transplantation. Transplantation 77:403-411, 2004.

• 5) Alexandre GPJ, Latinne D, Cianello P et al.:Preformed cytotoxic antibodies and ABO-incompatible grafts. Clin Transplantation 5:583-594, 1991.

• 6) Takahashi K, Yagisawa T, Sonoda K et al.:ABO-incompatible kidney transplantation in a single-center trial. Transplant Proc 25:271-273, 1993.

• 7) 齋藤和英, 高橋公太:わが国におけるABO血液型不適合腎移植の現況報告2007. ABO血液型不適合移植の新戦略2007. (高橋公太, 田中紘一・編) , 日本医学館, 2007, p3-17.

• 8) Tanabe M, Shimazu M, Wakabayashi G et al.:Intra-portal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73:1959-1961, 2002.

• 9) 江川裕人:ABO血液型不適合生体肝移植2007年集計報告. ABO血液型不適合移植の新戦略2007. (高橋公太, 田中紘一・編) , 日本医学館, 2007, p18-23.

• 10) Zecca M, De Stefano P, Nobili B, et al.:Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 97:3995-3997, 2001.
  pubmed

• 11) Sawada T, Fuchimoto S, Teraoka S et al.:Successful A1 to O, ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double filtration plasmapheresis. Transplantation 74:1207-1210, 2002.

• 12) Gloor JM, DeGoey SR, Pineda AA et al:Overcoming a positive crossmatch in living-donor kidney transplantation Am J Transpl 3:1017-1023, 2003.

• 13) Pierson III RN, Loyd JE, Goodwin A et al.:Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, compliment inhibition, and immonomodulatory therapy. Transplantation 74:79-84, 2002.

• 14) Aranda JM, Scornik JC, Normann SJ et al.:Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection:a case report. Transplantation 73:907-910, 2002.
  pubmed

P.51 掲載の参考文献

• 1) Egawa H, Teramukai S, Haga H et al.:Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 47:143-152, 2008.
  pubmed

• 2) Tanabe M, Shimazu M, Wakabayashi G et al.:Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73:1959-1961, 2002.
  pubmed

• 3) Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H et al.:Rituximab, IVIG and plasma exchange without graft local infusion treatment; A new protocol in ABO incompatible living donor liver transplantation. Transplantation 88:303-307, 2009.
  pubmed

• 4) Pescovitz MD:Rituximab, an anti-CD20 monoclonal antibody:history and mechanism of action. Am J Transplant 6:859-866, 2006.
  pubmed

• 5) Usui M, Isaji S, Mizuno S et al.:Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation. Clin Transplant 21:24-31, 2007.
  pubmed

• 6) Egawa H, Ohmori K, Haga H et al.:B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 13:579-588, 2007.
  pubmed

• 7) Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D:Intravenous gammaglobulin (IVIG) :a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 6:459-466, 2006.
  pubmed

• 8) Morioka D, Sekido H, Kubota K et al.:Antibody-mediated rejection after adult ABO-incompatible liver transplantation remedied by gamma-globulin bolus infusion combined with plasmapheresis. Transplantation 78:1225-1228, 2004.
  pubmed

• 9) Ikegami T, Taketomi A, Soejima Y et al.:Successful ABO incompatible living donor liver transplantation in a patient with high isoagglutinin titer using high-dose intravenous immunoglobulin. Transplant Proc 39(10) :3491-3494, 2007.

• 10) Urbani L, Mazzoni A, Bianco I et al.:The role of immunomodulation in ABO-incompatible adult liver transplant recipients. J Clin Apher 23:55-62, 2008.
  pubmed

P.57 掲載の参考文献

• 1) Egawa H, Oike F, Buhler L et al.:Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 77:403-411, 2004.
  pubmed

• 2) Egawa H, Ohmori K, Haga H et al.:B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 13:579-588, 2007.
  pubmed

• 3) 高橋公太:ABO血液型不適合腎移植における新しい知見-ABO血液型関連抗原による急性抗体関連型拒絶反応の分類. 移植 41(3) :243-254, 2006.
  Medical*Online

第16回ABO血液型不適合移植研究会より

P.72 掲載の参考文献

• 1) Sugiyama K, Isogai K, Toyama A et al. ; Cyclosporine pharmacological efficacy estimated by lymphocyte immunosuppressant sensitivity test before and after renal transplantation. J Clin Pharm Ther 34:539-545, 2009.
  pubmed

• 2) Sugiyama K, Isogai K, Horisawa S et al.:The phamlacological efficacy of mycophenolic acid before and after renal transplantation as estimated by the lymphocyte immunosuppressant sensitivity test (LIST) . Immunopharmacol immunotoxicol (in-press 2010) .
  pubmed

P.73 掲載の参考文献

• 3) Hirano T, Oka K, Takeuchi H et al:Clinical significance of glucocorticoid pharmacodynamics assessed by antilymphocyte action in kidney transplantation. Marked difference between prednisolone and methylprednisolone. Transplantation 57:1341-1348, 1994.
  pubmed

• 4) Sugiyama K, Satoh H, Saito K et al.:Immunosuppressive efficacy of mycophenolate mofetil when compared with azathioprine and mizoribine against peripheral lymphocytes from renal transplant recipients. Transpl Int 18:590-595, 2005.
  pubmed

• 5) Sugiyama K, Arakawa K, Satoh H et al.:Correlation between pharmacological efficacy of cyclosporine A and tacrolimus, evaluated by lymphocyte immunosuppressant-sensitivity test (LIST) with MTT assay procedure in renal transplant recipients. J lmmunoassay lmmumochem 27:195-205, 2006.

P.79 掲載の参考文献

• 1) 片山昭男, 小林孝彰, 打田和治・他:低抗体価症例に対する脾摘回避・抗CD20抗体非使用プロトコール. ABO血液型不適合移植の新戦略2009. (高橋公太, 田中紘一・編) , 日本医学館, 東京, 2009, p63-67.

• 2) Alexander GP et al:Splenectomy as a prerequisite for successful human ABO-incompatible renal transplantation. Transplant Proc 17:138-143, 1985.

• 3) Kaplan B, Gangemi A, Thielke J et al.:Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 83:99-100, 2007.
  pubmed

• 4) Sonnenday CJ, Warren DS, Cooper M et al.:Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4:1315-1322, 2004.
  pubmed

• 5) Gloor JM, Lager DJ, Fidler ME et al.:A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy on ABO-incompatible kidney transplantation. Transplantation 80:1572-1577, 2005.
  pubmed

• 6) Mongomery R, Locke JE, King KE et al.:ABO incompatible renal transplantation:A Paradigm ready for broad implementation. Transplantation 87:1246-1255, 2009.

P.87 掲載の参考文献

• 1) 剣持 敬, 浅野武秀, 西郷健一・他:わが国初の生体部分膵・腎同時移植の1症例. 移植 40:466-472, 2005.
  Medical*Online

• 2) Alexandre GPJ, Squiffelet JP, Bruyere MDE et al.:ABO incompatible related and unrelated living donor renal allografts. Transplan Proc 18:452-455, 1986.

• 3) Takahashi K, Yagisawa T, Sonoda K et al.:ABO-incomaptible kidney transplantation in a single center trial. Transplant Proc 25:271, 1993.

• 4) Gruessner RWG:Crossmatch positively and ABO incom-patibility. Transplantation of the pancreas. (eds. Gr lessner RWG, Surtherland DER) , Springer-Verlag, New York, 2004, p398-403.

• 5) Kenmochi T, Saigo K, Maruyama M et al:Results of kidney transplantation from ABO-incompatible living donors in a single institution. Transplant Proc 40:2289-2291, 2008.

• 6) Gruessner RWG, Sutherland DER:Simultaneous kidney and segmental pancreas transplants from living related donors-the first two successful cases. Transplantation 61:1265-1268, 1996.

P.92 掲載の参考文献

• 1) Tanabe M, Shimazu M, Wakabayashi G et al.:Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73:1959-1961, 2002.
  pubmed

• 2) Demetris AJ, Jaffe R, Tzakis A et al.:Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 132:489-502, 1988.
  pubmed

• 3) Egawa H, Teramukai S, Haga H et al.:Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 47:143-152, 2008.
  pubmed

• 4) Yoshizawa A, Sakamoto S, Ogawa K et al:New protocol of immunosuppression for liver transplantation across ABO barrier:the use of Rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc 37:1718-1719, 2005.
  pubmed

• 5) Usuda M, Fujimori K, Koyamada N et al.:Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 79:12-16, 2005.
  pubmed

• 6) Oya H, Sato Y, Yamamoto S et al:Thrombotic microangiopathy after ABO-incompatible living donor liver transplantation:a case report. Transplant Proc 40:2549-2551, 2008.
  pubmed

• 7) Miyata R, Shimazu M, Tanabe M et al.:Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation. Liver Transpl 13:1455-1462, 2007.
  pubmed

• 8) Ikegami T, Taketomi A, Soejima Y et al.:Rituximab, IVIG, and plasma exchange without graft local infusion treatment:a new protocol in ABO incompatible living donor liver transplantation. Transplantation 88:303-307, 2009.
  pubmed

• 9) Testa G, Vidanovic V, Chejfec G et al.:Adult living-donor liver transplantation with ABO-incompatible grafts. Transplantation 85:681-686, 2008.
  pubmed